FDA Grants AP Status for Brimonidine Tartrate ANDA216772
The FDA has granted Abbreviated Approval (AP) status for ANDA216772, a generic formulation of Brimonidine Tartrate submitted by Upsher Smith Labs.
Company
Pharmaceutical intelligence for Upsher Smith Labs with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.